# Effects of Once and Twice Daily Dosing Regimen of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes (MK-8835-040)

> **NCT01054300** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 52 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2
- Adult

## Interventions

- **DRUG:** Ertugliflozin 2 mg single dose
- **DRUG:** Ertugliflozin 2 mg split into twice daily
- **DRUG:** Ertugliflozin 4 mg single dose
- **DRUG:** Ertugliflozin 4 mg split into twice daily
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01054300
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-02-17
- **Primary completion:** 2010-04-07
- **Final completion:** 2010-04-07
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2019-11-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01054300

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01054300, "Effects of Once and Twice Daily Dosing Regimen of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes (MK-8835-040)". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT01054300. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*